ISCT Webinar: Vectors for Cell Therapies: Design, Process Development, and Commercialization
Organized by the ISCT Process and Product Development Subcommittee
Sponsored by GE Healthcare Bio-Sciences Corp. and Sartorius Stedim Biotech
Wednesday, March 28, 2018
08:00 PDT, 11:00 EDT, 16:00 BST
- Tom Brieva, PhD, Director, New Product Platform Process Development, Celgene Cellular Therapeutics, United States
- Anandita Seth, PhD, Head of Research & Technology, Viral Therapy, Lonza, United States
- Ken Cornetta, MD, Professor of Clinical Medical & Molecular Genetics, Indiana University, United States
- James Miskin, PhD, Chief Technical Officer, Oxford BioMedica, United Kingdom
About the Webinar:
The ability of cell therapies to impact disease is broadened when coupled with vector technologies that allow genetic modification or delivery of bioactive molecules. Harnessing such technologies to modify cell behavior requires the choice of a suitable vector, the development of a process to apply the vector to cells, and commercialization of vector supply.
Although lentiviral and gamma-retroviral vectors have been the focus of recent attention due to their role in the transformational outcomes realized in Chimeric Antigen Receptor modified T cells, there is a wide variety of viral and non-viral vectors available to cell therapies. These tools, ranging from transposons that deliver genetic material to exosomes that deliver cell signals, must be chosen and designed to be suitable for the cell therapy intent. Once a vector is chosen, sound process development is needed to achieve a reproducible cell modification. This includes defining the necessary properties of the vector as well as defining and optimizing the conditions under which vector modifications occur. As a vector-modified cell therapy advances in the clinic, the supply of vector must meet the same increasing quality as the cell therapy itself. This includes validation of the vector characterization assays and manufacturing process, establishment of a commercial process and facility, and meaningful vector specifications.
Registration for this Webinar has been sponsored by GE Healthcare Bio-Sciences Corp. and Sartorius Stedim Biotech. The views and content expressed in this Webinar have been provided by GE Healthcare Bio-Sciences Corp. and Sartorius Stedim Biotech and may not reflect the independent views of ISCT or an objective review of the products and services discussed.